Bakers Union and FELRA Health and Welfare Fund

Quarterly Review
January – June 2022

September 8, 2022

Optum Rx®

Today's Topics

1. Key Discussion Topics
2. Performance Summary
3. Trend
4. Top Disease States
5. Rebates
6. Outcomes
   - Clinical Outcomes
   - Vigilant Outcomes
   - VCS Outcomes
7. Drug Pipeline

Your OptumRx Team

Paul Marcus
VP, Client Management
Labor & Trust

Holly Agoney
Strategic Account Executive
Labor & Trust

Caroline Atwood
Director, Client Management
Labor & Trust

Autumn Leblanc
Pharmacy Account Manager
Labor & Trust

Fabian Gonzales
Pharmacy Service Specialist
Labor & Trust

Current Plan Design

- Deductible, Ben Max, MOOP, Copays

Plan 1 (group BFWRX):	
Deductible:	This plan has no deductible.
Benefit Maximum:	$2,000 per year for Growth Hormones medications only
Max out of Pocket:	$2,850 Individual / $5,700 Family

Plan 2 (group BFWRX2) & Plan 3 (group BFWRX3):	
Deductible:	This plan has no deductible.
Benefit Maximum:	$2,000 per year for Growth Hormones medications only
Max out of Pocket:	$1,850 Individual / $3,700 Family

Co-pays

Plan 1 (group BFWRX) & Plan 2 (group BFWRX2):			
Retail		**Mail**	
*Generic:	$10	*Generic:	$20
*Brand:	$15	*Brand:	$30
*NP Brand:	$30	*NP Brand:	$60
*Specialty:	Run trial claim for co-pay	*Specialty:	N/A

Plan 3 (group BFWRX3):	
Retail / Mail	
*Generic:	5% ($5 min.)
*Brand:	15% ($15 min.)
*NP Brand:	25% ($25 min.)
*Specialty:	Run trial claim for co-pay

- **Effective 7/1/19**
  - Diabetes Program
  - Comprehensive Ums
  - Vigilant Program
  - RxOTC Program
- **Effective 8/1/2020**
  - Orphan Drug Program
- **Effective 3/1/2021**
  - Opioid Mgmt – tighter refill window & UMs
- **Effective 7/1/2021**
  - Premium Formulary
  - Mandatory Mail (MSS)
- **Effective 1/1/2022**
  - Split-fill/Smart-fill
- **Effective 3/1/2022**
  - CCAA/VCS

Key Discussion Topics

- Per Member Per Month (PMPM) trend = -0.6% Specialty trend = -40.3%
- Specialty represents 0.9% of claims

- Top 5 disease states accounted for 74% of total plan paid
  - Top traditional disease state: Diabetes
  - Top specialty disease state: Inflammatory Conditions

- Rebates – Jan – June 2022
  - Estimated - $46,200

- Clinical Outcomes savings
  - **UM (PA, ST, QL)** – July 2021 – June 2022
    - Savings = $96,100
  - **Vigilant** – July 2021 - June 2022
    - Savings = $38,530
  - **VCS** – Jan – June 2022
    - Savings = $4,166

OptumRx®

Key Statistics

Key Statistics – Performance Summary

Client totals

627

AVG. ELIGIBLE MEMBERS

The key metrics here help highlight the changes Bakers Union and FELRA Health and Welfare Fund has experienced period over period.

- Eligibility has decreased by -59.
- Number of utilizers has decreased by -72.

Total Rxs

CURRENT
3,972

PREVIOUS
4,739

PERCENT CHANGE
-16.2%

Total plan paid

CURRENT
$429,543

PREVIOUS
$472,688

PERCENT CHANGE
-9.1%

Utilizers

CURRENT
392

PREVIOUS
464

PERCENT CHANGE
-15.5%

Key Statistics

Key statistics with benchmark comparison

Benchmark comparison 1
LABOR AND TRUST

Benchmark comparison 2
COMMERCIAL

Comparing metrics to benchmarks help showcase areas of focus.

- Client trend was -0.6%, compared to the benchmark trend of 11.5%
- Member Paid Share changed by 13.2% period over period, compared to the benchmark of -4.1%

Key statistics	Curr	Prev	Percent change	Curr	Percent change	Curr	Percent change
Average age	42.9	42.0	2.1%	36.7	1.0%	37.0	0.0%
Plan paid PMPM	$114.15	$114.84	-0.6%	$104.89	11.5%	$115.50	11.0%
Plan paid per Rx	$108.14	$99.74	8.4%	$141.46	11.3%	$144.02	10.6%
Rxs PMPM	1.056	1.151	-8.3%	0.741	0.2%	0.802	0.4%
Average days supply	29.1	26.9	8.2%	39.3	1.0%	39.2	1.7%
Days supply PMPM	30.8	31.0	-0.8%	29.1	1.3%	31.5	2.1%
Member paid share	9.6%	8.4%	13.2%	11.1%	-4.1%	12.8%	-1.1%
Member paid per Rx	$11.42	$9.19	24.3%	$17.73	6.2%	$21.20	9.2%
Generic dispensing rate	82.9%	78.9%	5.1%	86.7%	1.7%	85.5%	2.0%
GDR-without Vaccines	86.7%	88.5%	-2.0%	89.1%	-0.1%	88.1%	-0.8%
Home delivery rate	4.4%	1.2%	255.9%	7.3%	1.9%	5.3%	0.6%
Retail 90 rate	1.2%	3.8%	-67.2%	15.6%	5.8%	19.2%	5.1%
Percent of specialty plan paid	19.9%	33.2%	-39.9%	46.4%	3.9%	50.8%	1.9%

Specialty Key Statistics

Client totals

627

AVG. ELIGIBLE MEMBERS

The key metrics here help highlight the changes Bakers Union and FELRA Health and Welfare Fund has experienced period over period.

- Eligibility has decreased by -59.
- Number of utilizers was unchanged.

Total Rxs

CURRENT
36

PREVIOUS
33

PERCENT CHANGE
9.1%

Total plan paid

CURRENT
$85,631

PREVIOUS
$156,829

PERCENT CHANGE
-45.4%

Utilizers

CURRENT
5

PREVIOUS
5

PERCENT CHANGE
-

Specialty Key Statistics

Key statistics with benchmark comparison

Benchmark comparison 1

LABOR AND TRUST

Benchmark comparison 2

COMMERCIAL

Comparing metrics to benchmarks help showcase areas of focus.

- Client trend was -40.3%, compared to the benchmark trend of 15.9%
- Member Paid Share changed by 1,550.7% period over period, compared to the benchmark of 0.1%

Key statistics	Curr	Prev	Percent change	Curr	Percent change	Curr	Percent change
Plan paid PMPM	$22.76	$38.10	-40.3%	$48.68	15.9%	$58.66	13.1%
Plan paid per Rx	$2,378.64	$4,752.40	-49.9%	$5,919.86	5.5%	$5,978.55	5.5%
Rxs PMPM	0.010	0.008	19.3%	0.008	9.8%	0.010	7.2%
Average days supply	29.0	29.2	-0.5%	32.8	2.2%	32.4	1.5%
Days supply PMPM	0.3	0.2	18.7%	0.3	12.3%	0.3	8.9%
Member paid share	4.9%	0.3%	1,550.7%	7.3%	0.1%	7.2%	10.9%
Member paid per Rx	$123.36	$14.24	766.2%	$463.12	5.6%	$460.96	17.9%
Generic dispensing rate	50.0%	15.2%	230.0%	22.7%	-2.6%	20.5%	-6.2%
Home delivery rate	2.8%	0.0%	0.0%	5.2%	-7.0%	3.9%	-5.8%
Retail 90 rate	0.0%	0.0%	0.0%	5.5%	18.3%	6.0%	6.4%

Trend Summary

Trend Summary

Trend

Plan paid PMPM has decreased -0.6% over the previous period driven primarily by drug mix in traditional and drug mix for specialty.

Specialty represents 0.9% of claims.

-0.6%	19.1%	-40.3%
TOTAL TREND	TRADITIONAL TREND	SPECIALTY TREND
-12.2% under benchmark	**+11.1%** over benchmark	**-56.2%** under benchmark

Traditional vs. Specialty Trend Components

Traditional trend: 19.1%

Benchmark comparison: LABOR AND TRUST

- Traditional trend contributed -2,116.4% to the overall trend (-0.6%)
- Traditional accounts for 80.1% of overall total plan paid and was up from 66.8% in the prior period



Specialty trend: -40.3%

Benchmark comparison: LABOR AND TRUST

- Specialty trend contributed 2,216.4% to the overall trend (-0.6%)
- Specialty accounts for 19.9% of overall total plan paid and was down from 33.2% in the prior period



OptumRx®

Top Disease States
&
Top 20 Drugs

Optum Rx®

TRADITIONAL SPECIALTY

Top Disease States

Top 5 disease states account for 74% of total Plan Paid

- Diabetes accounts for 26.1% of total plan paid, with trend driven by Utilization. VICTOZA was the top drug
- Inflammatory Conditions accounts for 18.8% of total plan paid, with trend driven by Utilization. DUPIXENT was the top drug

Sort by: Plan Paid

Disease State	PMPM	Trend	Top driver
Diabetes	$29.75	8.5%	Utilization
Inflammatory Conditions	$21.49	-43.7%	Utilization
Asthma / COPD	$13.47	158.9%	Utilization
HIV	$11.80	23.8%	Drug Mix
Cardiovascular	$8.09	14.8%	Drug Mix
All other	$29.54	7.5%	

Top 20 Drugs by Plan Cost

Specialty

All meds are Brands

Rank														Trend components		
Cu	Pv	Bench	Drug name		Therapy class	Utlzr	Rxs	Avg days supply	Total plan paid	Plan paid per Rx	Curr plan paid PMPM	Prev plan paid PMPM	Bench plan paid PMPM	% Trend	Top driver	% Top driver
1	4	6	DUPIXENT		Chronic Inflammatory Disease	2	12	28.0	$39,287	$3,273.90	$10.44	$5.73	$1.96	82.3%	Utlzn	87.5%
2	2	1	HUMIRA PEN		Chronic Inflammatory Disease	1	6	28.0	$37,640	$6,273.28	$10.00	$10.51	$7.44	-4.8%	Cost	6.4%
3	5	246	STRIBILD		HIV-Multiclass Combo	1	5	30.0	$18,469	$3,693.86	$4.91	$4.22	$0.06	16.4%	Utlzn	9.4%
4	6	10	BIKTARVY		HIV-Multiclass Combo	1	5	30.0	$16,063	$3,212.55	$4.27	$2.85	$1.64	49.8%	Utlzn	36.7%
5	20	32	SYMBICORT		Inhaled Asthma/COPD Combo	5	44	32.7	$15,678	$356.33	$4.17	$1.15	$0.60	261.4%	Utlzn	275.0%
6	7	30	VICTOZA	★	GLP-1 Receptor Agonists	2	12	35.0	$14,218	$1,184.85	$3.78	$2.84	$0.61	33.2%	Utlzn	27.6%
7	14	4	TRULICITY	★	GLP-1 Receptor Agonists	4	15	28.0	$11,933	$795.55	$3.17	$1.58	$3.12	100.6%	Utlzn	105.1%
8	11	5	JARDIANCE	★	SGLT-2 Inhibitors & Combos	6	23	30.0	$11,748	$510.79	$3.12	$2.17	$2.71	44.1%	Utlzn	67.7%
9	15	21	JANUMET	★	DPP-4 Inhibitors & Combos	3	15	38.0	$9,229	$615.27	$2.45	$1.48	$0.84	65.2%	Utlzn	59.9%
10	64	44	BREO ELLIPTA		Inhaled Asthma/COPD Combo	2	26	30.0	$9,103	$350.13	$2.42	$0.33	$0.41	631.8%	Utlzn	611.0%
11	12	193	PREZCOBIX		HIV-Multiclass Combo	1	2	60.0	$8,288	$4,143.96	$2.20	$1.93	$0.08	14.2%	Utlzn	9.4%
12	17	33	ENTRESTO		Angiotensin II Receptor & Neprilysin Inhibitor (ARNI)	2	11	35.5	$7,658	$696.20	$2.04	$1.34	$0.59	51.6%	Utlzn	42.2%
13	10	125	LANTUS	★	Insulin	4	9	25.6	$6,798	$755.32	$1.81	$2.25	$0.16	-19.6%	Utlzn	-33.8%
14	59	38	ADVAIR DISKUS		Inhaled Asthma/COPD Combo	4	16	30.0	$6,763	$422.67	$1.80	$0.35	$0.49	415.1%	Utlzn	483.4%
15	8	9	JANUVIA	★	DPP-4 Inhibitors & Combos	3	13	30.0	$6,473	$497.91	$1.72	$2.58	$1.70	-33.2%	Utlzn	-37.0%
16	-	70	CREON		Digestive Enzymes	1	3	30.0	$5,952	$1,984.14	$1.58	$0.00	$0.28	-	-	-
17	28	7	ELIQUIS		Oral Anticoagulants	5	12	29.8	$5,877	$489.76	$1.56	$0.69	$1.83	125.9%	Utlzn	117.5%
18	23	11	LANTUS SOLOSTAR	★	Insulin	7	15	30.0	$5,808	$387.23	$1.54	$0.92	$1.39	68.0%	Utlzn	59.3%
19	19	92	DEXILANT		Proton Pump Inhibitors	3	18	30.0	$5,193	$288.50	$1.38	$1.26	$0.21	9.7%	Utlzn	9.4%
20	16	3	OZEMPIC	★	GLP-1 Receptor Agonists	2	2	84.0	$4,819	$2,409.39	$1.28	$1.38	$3.37	-7.5%	Utlzn	-12.5%
Total						43	264	31.6	$246,998	$935.60	$65.64	$45.56	$29.49	44.1%		67.9%
Plan Total						392	3,972	29.2	$429,543	$108.14	$114.15	$114.84	$104.89	-0.6%		6.4%

★ Diabetes meds (8)

15 out of the top 20 have moved up in rank

Optum Rx®

Rebates

Rebate Performance Summary

Outcomes date range: Jan - Jun 2022
Benchmark: LABOR AND TRUST

Current rebate value: $12.28 PMPM

10.8%
REBATE IMPACT

Rebate impact on Plan Paid PMPM

Managing drug spend to a lowest net cost PMPM is achieved through adoption of high performing formulary strategies and driving to lowest net cost products when clinically appropriate. Bakers Union and FELRA Health and Welfare Fund's members adherence to the formulary has earned an offset on PMPM costs, yielding a net plan paid PMPM of $101.87, versus plan paid PMPM of $114.15.

Net financial PMPM performance

	Drug cost	Member Paid	Plan Paid	Rebates	Net plan paid
Traditional	$102.26	$10.87	$91.39	$10.13	$81.26
Specialty	$23.94	$1.18	$22.76	$2.15	$20.60
Total	$126.19	$12.05	$114.15	$12.28	$101.87

Total estimated rebate yield for reporting period: **$46.2K**

Optum Rx®

Rebate Performance by Disease State

Disease	Drug cost PMPM	Member paid PMPM	Plan paid PMPM	Rebates PMPM	Net plan paid PMPM	Rebate offset
Diabetes	$31.58	$1.82	$29.75	$4.52	$25.23	15.2%
Inflammatory Conditions	$22.65	$1.16	$21.49	$2.15	$19.34	10.0%
Asthma / COPD	$14.18	$0.71	$13.47	$1.83	$11.64	13.6%
Cardiovascular	$10.11	$2.02	$8.09	$0.68	$7.41	8.4%
Diabetes Monitoring and Testing Supplies	$0.59	$0.07	$0.52	$0.67	-$0.15	128.9%
Ulcer/Acid Reflux/Gerd	$1.97	$0.20	$1.77	$0.43	$1.34	24.3%
HIV	$12.37	$0.57	$11.80	$0.29	$11.52	2.4%
Blood Clot Prevention/Stroke Prevention	$2.13	$0.16	$1.97	$0.26	$1.71	13.3%
Diabetic Supplies	$1.77	$0.18	$1.59	$0.24	$1.35	15.1%
Cholesterol Lowering Agents	$5.08	$1.07	$4.01	$0.21	$3.80	5.2%
Gastrointestinal, Misc	$1.80	$0.06	$1.74	$0.19	$1.55	11.0%
Ophthalmic Agents	$1.14	$0.09	$1.05	$0.14	$0.91	13.7%
Male And Female Hormone Replacement	$0.80	$0.07	$0.74	$0.12	$0.62	16.2%
Anti-Inflammatory (Steroids)	$0.18	$0.07	$0.11	$0.10	$0.01	89.2%
Overactive Bladder / Incontinence	$0.70	$0.03	$0.66	$0.07	$0.59	10.8%
Contraception	$1.34	$0.02	$1.33	$0.07	$1.26	5.4%
Narcotic Analgesics	$0.23	$0.11	$0.13	$0.05	$0.08	38.1%
Severe Allergic Reaction	$0.14	$0.01	$0.13	$0.05	$0.08	36.4%
Migraine/Pain Relief	$0.51	$0.08	$0.43	$0.05	$0.38	11.1%
Antibiotics	$0.83	$0.30	$0.53	$0.05	$0.48	9.0%
Glaucoma	$0.83	$0.05	$0.78	$0.05	$0.74	6.1%
Ear Condition	$0.27	$0.02	$0.25	$0.02	$0.23	9.6%
Antipsychotics	$0.74	$0.18	$0.57	$0.02	$0.54	4.2%
Seizure Disorders	$1.61	$0.27	$1.34	$0.02	$1.32	1.8%

Clinical Outcomes

UM Outcomes

Outcomes date range: Jul 2021 - Jun 2022

Utilization management savings: $12.66 PMPM

Your program savings: **$96.1K**

Ensuring patients meet appropriate clinical criteria when initiating medication therapy not only helps to ensure that the patient is being treated safely according to guidelines, but also drives significant savings for both Bakers Union and FELRA Health and Welfare Fund and for members. Bakers Union and FELRA Health and Welfare Fund has realized over $96.1K in savings. Based on a study by OptumRx, leveraging UM strategies that drive members to appropriate and often lower cost medications for treatment can save a member up to $620 annually in out of pocket copayments.



Outcomes date range: Jul 2021 - Jun 2022

Prior authorization

PMPM SAVINGS
$4.29

NUMBER OF MEMBERS IMPACTED
33

NUMBER OF INTERVENTIONS
41

Quantity limits

PMPM SAVINGS
$5.47

NUMBER OF MEMBERS IMPACTED
8

NUMBER OF INTERVENTIONS
9

Step therapy

PMPM SAVINGS
$2.91

NUMBER OF MEMBERS IMPACTED
79

NUMBER OF INTERVENTIONS
97

QL savings is based only on Maximum Daily Dose edits.

Vigilant Outcomes

Outcomes date range: Jul 2021 - Jun 2022

Total program savings: $5.08 PMPM

Vigilant Drug Outcomes – Cost Avoidance

By leveraging the Vigilant Drug Program, Bakers Union and FELRA Health and Welfare Fund has:

- Avoided $38.5K in pharmacy spend
- Switched 14 claims to lower cost alternatives
- 5 claims were abandoned

$5.08
TOTAL PMPM SAVINGS

TOTAL PLAN PAID SAVINGS
$38,530

TOTAL PROGRAM SAVINGS
4.4%

TOTAL MEMBERS IMPACTED
20

Savings by Vigilant Drug List

Sort by: Members impacted Plan paid PMPM savings

Vigilant drug list	PMPM savings	Members impacted	Interventions
High Cost Generics	$0.41	8	8
Clinical Duplicates	$1.42	6	6
High Cost Brands with Generics	$2.98	3	3
Non-FDA Approved Drugs	$0.02	2	2
New Drugs to Market	$0.26	1	1

VCS Copay Solutions Outcomes

Outcomes date range: Jan - Jun 2022

Total program savings: $1.11 PMPM

Variable copay program savings outcomes

With the OptumRx Variable Copay program, Bakers Union and FELRA Health and Welfare Fund has realized:

- $4,166 in Plan Paid savings
- $694.33 average Plan Paid per impacted prescription
- 2 total impacted utilizers
- 6 prescriptions processed through the program out of a possible 19 eligible prescriptions

PLAN PAID SAVINGS

$4,166

PLAN PAID SAVINGS PER IMPACTED RX

$694.33

Top 5 drugs based on: Plan paid savings Impacted Rxs

DUPIXENT	HUMIRA PEN
IMPACTED RXS: 2	IMPACTED RXS: 4
IMPACTED UTILIZERS: 1	IMPACTED UTILIZERS: 1
PLAN PAID SAVINGS: $2,166	PLAN PAID SAVINGS: $2,000

Optum Rx®

Drug Pipeline

Selected generic launches in 2022 and early 2023

2021 US Sales

Blockbuster drug
(>$1B in annual U.S. sales)

2Q:2022

- **Toviaz** (fesoterodine): Overactive bladder
- **Dulera** (formoterol fumarate/ mometasone furoate): Asthma
- **Jevtana** (cabazitaxel): Prostate cancer
- **Pradaxa** (dabigatran): Reduce stroke/atrial fibrillation
- **Velcade** (bortezomib): Cancer **$1.4B**
- **Alimta** (pemetrexed): Cancer **$1.6B**
- **Viibyrd** (vilazodone): Depression

3Q:2022

- **Flovent HFA** (fluticasone propionate): Asthma; COPD **$2B**
- **Suprep** (magnesium/potassium/sodium sulfates)†: Colonscopy prep

4Q:2022

- **Treanda** (bendamustine): Cancer
- **Zioptan** (tafluprost): Glaucoma

1Q:2023

- **Myrbetriq** (mirabegron): Overactive bladder **$2.5B**
- **Esbriet** (pirfenidone): Idiopathic pulmonary fibrosis
- **Spiriva** (tiotropium) †: Asthma; COPD **$1.8B**
- **Xyrem** (sodium oxybate) †: Cataplexy; narcolepsy **$1.4B**

† Generic has 180-days of exclusivity
COPD = Chronic obstructive pulmonary disease

Biosimilar landscape

Larger financial impact likely to occur starting 2023

Biosimilar products currently in the marketplace

Innovator Brand	Herceptin	Rituxan	Avastin	Neupogen	Epogen / Procrit	Neulasta	Remicade*	Lantus
Biosimilar Product	Kanjinti Ogivri Trazimera Herzuma Ontruzant	Truxima Ruxience Riabni	Mvasi Zirabev	Zarxio Nivestym	Retacrit	Fulphila Udenyca Ziextenzo Nyvepria	Inflectra Renflexis Avsola	Semglee† insulin glargine-yfgn†

Brands with biosimilars in the pipeline (and 2021 US sales)

2022
- Lucentis **($2.3B)**
- Novolog/Flexpen* **($6.1B)**

2023
- Humira† **($17.3B)**
- Eylea **($5.2B)**
- Neulasta Onpro **($4.2B)**

2024
- Actemra **($2.1B)**
- Stelara **($10.6B)**
- Simponi/Aria **($4.2B)**

2025
- Prolia **($2.7B)**
- Soliris **($2.6B)**

2029
- Enbrel **($8.5B)**

*Possible interchangeability
† Interchangeability granted
2020 U.S. Sales: IPD Analytics

Eleven Humira (adalimumab) biosimilars are expected to launch in 2023

Brand Name (Generic Name)	**Manufacturer**	**Interchangeability**	**FDA Approval Date**	**US Launch Date**
Approved Humira biosimilars				
Amjevita (adalimumab-atto)	Amgen	In clinical trials	9/23/2016	1/31/2023
Cyltezo (adalimumab-adbm)	Boehringer Ingelheim	Approved	8/25/2017	7/1/2023
Hyrimoz (adalimumab-adaz)	Sandoz		10/31/2018	7/1/2023
Hadlima (adalimumab-bwwd)	Samsung Bioepis/Organon	In clinical trials	7/23/2019	7/1/2023
Abrilada (adalimumab-afzb)	Pfizer	Filed, expected 4Q2022	11/18/2019	7/1/2023
Hulio (adalimumab-fkjp)	Viatris		7/6/2020	7/2023
Yusimry (adalimumab-aqvh)	Coherus		12/20/2021	7/1/2023
Humira biosimilars in the pipeline				
AVT-02*	Teva/Alvotech	Filed, expected 12/2022	1H2022	7/1/2023
Yuflyma*	Celltrion		8/2022	7/1/2023
SB5*	Samsung Bioepis/ Organon	In clinical trials	11/2022	7/1/2023
MSB-11022	Fresenius Kabi		1Q2023	9/30/2023

* AVT-02, Yuflyma, and SB5 will be citrate-free formulations available as 100 mg/mL strength (lower volume formulations).
1. Organon is a spinoff from Merck, partnering with Samsung Bioepis
2. Viatris is a combination of Mylan, and the former Pfizer Upjohn business

Appendix

Trend Components

Total trend: -0.6%

Benchmark comparison: LABOR AND TRUST

- Bakers Union and FELRA Health and Welfare Fund's overall trend of -0.6% was -12.2% lower than benchmark
- Specialty spend influenced the trend contributing 2216.4% (2155.0% higher than benchmark)
- Traditional trend contributed -2116.4% (2155.0% lower than benchmark)



Top 20 traditional

All meds are Brands

Rank													Trend components		
Cu	Pv	Bench	Drug name	Therapy class	Utlzr	Rxs	Avg days supply	Total plan paid	Plan paid per Rx	Curr plan paid PMPM	Prev plan paid PMPM	Bench plan paid PMPM	% Trend	Top driver	% Top driver
1	1	125	STRIBILD	HIV-Multiclass Combo	1	5	30.0	$18,469	$3,693.86	$4.91	$4.22	$0.06	16.4%	Utlzn	9.4%
2	2	6	BIKTARVY	HIV-Multiclass Combo	1	5	30.0	$16,063	$3,212.55	$4.27	$2.85	$1.64	49.8%	Utlzn	36.7%
3	16	16	SYMBICORT	Inhaled Asthma/COPD Combo	5	44	32.7	$15,678	$356.33	$4.17	$1.15	$0.60	261.4%	Utlzn	275.0%
4	3	15	VICTOZA	GLP-1 Receptor Agonists	2	12	35.0	$14,218	$1,184.85	$3.78	$2.84	$0.61	33.2%	Utlzn	27.6%
5	10	2	TRULICITY	GLP-1 Receptor Agonists	4	15	28.0	$11,933	$795.55	$3.17	$1.58	$3.12	100.6%	Utlzn	105.1%
6	7	3	JARDIANCE	SGLT-2 Inhibitors & Combos	6	23	30.0	$11,748	$510.79	$3.12	$2.17	$2.71	44.1%	Utlzn	67.7%
7	11	11	JANUMET	DPP-4 Inhibitors & Combos	3	15	38.0	$9,229	$615.27	$2.45	$1.48	$0.84	65.2%	Utlzn	59.9%
8	59	22	BREO ELLIPTA	Inhaled Asthma/COPD Combo	2	26	30.0	$9,103	$350.13	$2.42	$0.33	$0.41	631.8%	Utlzn	611.0%
9	8	99	PREZCOBIX	HIV-Multiclass Combo	1	2	60.0	$8,288	$4,143.96	$2.20	$1.93	$0.08	14.2%	Utlzn	9.4%
10	13	17	ENTRESTO	Angiotensin II Receptor & Neprilysin Inhibitor (ARNI)	2	11	35.5	$7,658	$696.20	$2.04	$1.34	$0.59	51.6%	Utlzn	42.2%
11	6	75	LANTUS	Insulin	4	9	25.6	$6,798	$755.32	$1.81	$2.25	$0.16	-19.6%	Utlzn	-33.8%
12	54	19	ADVAIR DISKUS	Inhaled Asthma/COPD Combo	4	16	30.0	$6,763	$422.67	$1.80	$0.35	$0.49	415.1%	Utlzn	483.4%
13	4	5	JANUVIA	DPP-4 Inhibitors & Combos	3	13	30.0	$6,473	$497.91	$1.72	$2.58	$1.70	-33.2%	Utlzn	-37.0%
14	-	35	CREON	Digestive Enzymes	1	3	30.0	$5,952	$1,984.14	$1.58	$0.00	$0.28	-	-	-
15	24	4	ELIQUIS	Oral Anticoagulants	5	12	29.8	$5,877	$489.76	$1.56	$0.69	$1.83	125.9%	Utlzn	117.5%
16	19	7	LANTUS SOLOSTAR	Insulin	7	15	30.0	$5,808	$387.23	$1.54	$0.92	$1.39	68.0%	Utlzn	59.3%
17	15	52	DEXILANT	Proton Pump Inhibitors	3	18	30.0	$5,193	$288.50	$1.38	$1.26	$0.21	9.7%	Utlzn	9.4%
18	12	1	OZEMPIC	GLP-1 Receptor Agonists	2	2	84.0	$4,819	$2,409.39	$1.28	$1.38	$3.37	-7.5%	Utlzn	-12.5%
19	5	718	HUMALOG MIX 50/50 KWIKPEN	Insulin	1	2	90.0	$4,775	$2,387.35	$1.27	$2.26	$0.01	-44.0%	Utlzn	-39.6%
20	17	47	BYDUREON BCISE	GLP-1 Receptor Agonists	1	6	29.0	$4,505	$750.88	$1.20	$1.06	$0.22	13.0%	Utlzn	13.3%
Total					41	254	32.2	$179,352	$706.11	$47.66	$32.64	$20.32	46.0%		61.9%
Plan Total					391	3,936	29.2	$343,912	$87.38	$91.39	$76.74	$56.21	19.1%		10.4%

Diabetes meds – 10 out of the top 20

10 out of the top 20 have moved up in rank

Top 20 specialty

B = Brands
G = Generics

Rank													Trend components		
Cu	Pv	Bench	Drug name	Therapy class	Utlzr	Rxs	Avg days supply	Total plan paid	Plan paid per Rx	Curr plan paid PMPM	Prev plan paid PMPM	Bench plan paid PMPM	% Trend	Top driver	% Top driver
1	4	3	DUPIXENT B	Chronic Inflammatory Disease	2	12	28.0	$39,287	$3,273.90	$10.44	$5.73	$1.96	82.3%	Utlzn	87.5%
2	2	1	HUMIRA PEN B	Chronic Inflammatory Disease	1	6	28.0	$37,640	$6,273.28	$10.00	$10.51	$7.44	-4.8%	Cost	6.4%
3	3	9	OTEZLA B	Chronic Inflammatory Disease	1	0	0.0	$3,941	$0.00	$1.05	$9.56	$1.09	-89.0%	Utlzn	-100.0%
4	5	152	MYCOPHENOLATE MOFETIL G	Transplant	1	6	30.0	$2,943	$490.52	$0.78	$0.42	$0.05	87.7%	Cost	54.5%
5	-	147	TACROLIMUS G	Transplant	1	12	30.0	$1,821	$151.73	$0.48	$0.00	$0.05	-	-	-
Total					5	36	29.0	$85,631	$2,378.64	$22.76	$38.10	$11.84	-40.3%		-50.9%
Plan Total					5	36	29.0	$85,631	$2,378.64	$22.76	$38.10	$48.68	-40.3%		-50.9%

Optum Rx®

3 out of the top 5 are for Chronic Inflammatory Disease

3 out of the top 5 have moved up in rank